Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
:FGEN
FGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.50 - $21.94
Previous CloseN/A
Volume937.77K
Average Volume (3M)40.43K
Market Cap
$27.93M
Enterprise Value$130.86M
Total Cash (Recent Filing)$33.61M
Total Debt (Recent Filing)$73.42M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 11, 2025EPS Estimate
-2.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding4,041,759
10 Day Avg. Volume22,388
30 Day Avg. Volume40,430
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.69
Enterprise Value/Revenue-5.56
Enterprise Value/Gross Profit-9.62
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$250.00Price Target Upside3517.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StrengthThe strong cash balance permits both flexibility and boosts confidence that FG-3246's clinical endeavors can progress without interruption.
Regulatory ProgressManagement conveyed that interactions with the FDA have progressed in a timely manner with no delays, despite investor uncertainties.
Strategic TransactionsThe sale of FibroGen China to AstraZeneca is considered a strategic transaction, providing FibroGen with additional capital and streamlining its portfolio.
Bears Say
Legal And Financial PenaltiesAnnounced a settlement related to roxadustat, which will result in a $1.25 million civil penalty paid to FibroGen.
Pipeline ChallengesThe focus remains on Pamrevlumab, especially after the latest Roxa setback, indicating continued strategic pipeline development.
Strategic ChallengesCorporate focus shifts to mCRPC ADC and potentially MDS, signaling a complex strategic realignment.
FibroGen News
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $4.50 and its highest was $21.94 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $27.93M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on May 12, 2025. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.5.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -2.3.
How many shares outstanding does FibroGen have?
FibroGen has 4,041,759 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of $1.25 in its last earnings report, beating expectations of $0.75. Following the earnings report the stock price went down -2.094%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$250.00 (3517.95% Upside)
$250.00 (3517.95% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 35.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $119.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.40%
12-Months-Change
Fundamentals
Return on Equity
60.38%
Trailing 12-Months
Asset Growth
-54.84%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FGEN Company Deck
FGEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a transformative period for FibroGen, with the sale of FibroGen China to AstraZeneca bringing in higher than expected proceeds and extending their financial runway significantly. There is notable progress in their clinical pipeline, particularly in the development of FG-3246 and FG-3180, with promising results from clinical trials. However, the company faced a significant decline in revenue and continued to operate at a net loss. While the highlights indicate strategic advancements and positive financial prospects, the revenue decline and continued net loss are concerning.View all FGEN earnings summariesFGEN Stock 12 Month Forecast
Average Price Target
$250.00
▲(3517.95% Upside)
Technical Analysis
Ownership Overview
1.57% Insiders
10.40% Mutual Funds
13.04% Other Institutional Investors
70.24% Public Companies and
Individual Investors